In a significant development for Inspire Medical Systems, Inc., a class action lawsuit has been filed against the company and its senior executives by Grant & Eisenhofer P.A. on behalf of the City of Pontiac Reestablished General Employees’ Retirement System. The lawsuit, initiated today, accuses Inspire Medical and its top executives, including CEO Timothy Herbert, CFO Richard Buchholz, and Chief Strategy and Growth Officer Carlton Weatherby, of defrauding investors by providing materially false and misleading statements concerning the launch of its new sleep apnea device, Inspire V.

2. Allegations of Misrepresentation

According to the complaint, which was filed in the United States District Court for the District of Minnesota, the lawsuit alleges that throughout the Class Period—from August 6, 2024, to August 4, 2025—Defendants failed to disclose critical information regarding the Inspire V device. Key points of concern include:

Market Demand: The lawsuit claims that executives misrepresented the actual market demand for Inspire V, leading investors to believe that interest in the product was robust.

Launch Readiness: It is alleged that the company did not adequately prepare for a successful launch of the device, including failing to ensure that necessary training and onboarding were completed at treatment centers before the product rollout.

The complaint cites violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, highlighting the seriousness of the alleged misleading statements.

3. The Launch and Subsequent Fallout

Inspire Medical Systems develops an implantable device designed to treat obstructive sleep apnea. The latest version, Inspire V, utilizes a sensor and neurostimulator to enhance respiration during sleep. However, the anticipated launch faced numerous challenges.

On August 4, 2025, the company disclosed that the rollout of Inspire V was experiencing an "elongated timeframe" due to issues such as incomplete training and onboarding at many medical centers. Additionally, while Inspire V had received a CPT code approval for Medicare patients, the necessary software updates for billing did not take effect until July 1. This delay resulted in treatment centers opting to continue using the earlier version, Inspire IV, rather than adopting the new device.

As a result of these revelations, the company announced a staggering reduction in its 2025 earnings guidance by over 80%. The immediate market response was severe, with Inspire Medical’s stock plummeting more than 32% in a single day—from $129.95 per share to $87.91—erasing approximately $1.2 billion in market capitalization.

4. Financial Impact and Investor Response

The fallout from the launch failure has been substantial. Since reaching a Class Period high of $216.71 per share on September 23, 2024, Inspire Medical's stock has experienced a dramatic decline, losing nearly 60% of its value and erasing billions in market capitalization. The lawsuit has drawn attention from investors who purchased shares during the Class Period, as they may be eligible to seek appointment as lead plaintiffs.

5. Next Steps for Affected Investors

Investors who acquired Inspire Medical common stock during the specified Class Period are considered part of the proposed class. They may seek to serve as lead plaintiffs by moving the court by January 5, 2026. Although it is not necessary to be appointed as a lead plaintiff to share in any potential recovery, affected investors are encouraged to consult legal counsel regarding their rights and options.

The unfolding situation presents a cautionary tale regarding the vital importance of transparency and accurate communication in the financial markets, particularly when it comes to new product launches and investor relations. As the lawsuit progresses, the implications for Inspire Medical and its leadership will be closely watched by the market and investors alike.

Original press release